【文/王力 编辑/周毅】 近日，美国天然产品协会（NPA）官网发布消息称，美国食品药品监督管理局（FDA）正式确认此前备受争议的"不老神药"β-烟酰胺单核苷酸（NMN）可作 为膳食补充剂合法销售。 然而，监管松绑的背后，是一场深刻的中美产业博弈。当FDA以"安全备案"为NMN亮起绿灯时，手握全球90%原料产能的中国企业，却因国内审慎的监管 态度而陷入"原料出口、成品难归"的产业困局。金达威、雅本化学等头部企业不得不借道跨境电商，将本土生产的原料运往海外工厂加工后再"绕道"回国。 此外，科学界的争议更为这场商业盛宴蒙上阴影。尽管动物实验显示NMN能逆转老年小鼠细胞年龄，但截止发稿前，全球仅有19项人体临床试验注册， 《柳叶刀》更直指其"临床证据不足、作用机制不明"。 每日摄入成本可达数十元至上百元，年花费数万元，这将目标客户群体限定在高净值人群。这种性价比质疑使得NMN即便在监管宽松的美日市场，也未能 突破小众圈层。获得李嘉诚投资的Chroma Dex公司业绩不达预期，其财务报表印证了市场理性的回归——并非所有消费者都愿意为未经充分验证的"长生不 老"概念买单。 监管松绑与产业格局：中美博弈下的市场分水岭 FD ...

美国一项新研究证实,富含黄烷醇的可可提取物补充剂能降低老年人血液中的关键炎症指标,这表明它在 保护心脏方面具有重要作用,也进一步证实了富含黄烷醇的植物性食物对于延缓炎症性衰老的潜在价 值。研究发现,服用可可提取物补充剂的参与者体内超敏C反应蛋白水平下降,这种蛋白是预示心血管疾 病风险的炎症标志物。这表明可可的抗炎特性或能解释其护心作用。新华 ...

研究团队首先对约7500人的健康数据进行分析，进而利用8000多份血液样本对模型进行验证。结果 显示，与传统表观遗传时钟相比，新方法不仅能更准确地预测心脏病等与衰老相关的特定疾病，还能揭 示不同个体内各系统衰老模式的显著差异。 科技日报北京9月25日电 （记者刘霞）瑞典卡罗林斯卡学院与美国耶鲁大学科学家合作开发出一项 新型血液检测技术——"系统年龄检测法"，能够通过一次抽血，全面评估人体11个不同生理系统的衰老 状况，为个性化健康管理提供更精准依据。相关研究成果发表于最新一期《自然·衰老》杂志。 人体各个器官和系统的衰老速度并不一致，受遗传、环境、生活方式等多重因素影响。传统生物年 龄检测方法只能给出一个整体性数值，无法反映不同部位的衰老差异。 新方法基于表观遗传学中的DNA甲基化机制，通过分析血液中特定生物标志物（如胆固醇、血糖 等）与各器官衰老相关疾病之间的关联，结合机器学习技术，建立起能评估心脏、肺、脑、代谢系统、 免疫系统等11个生理系统年龄的预测模型。 团队表示，该检测技术可为临床提供更具针对性的干预指导。例如，若检测发现某人的免疫系统年 龄显著高于心脏或肺部，医生可建议其采取增强免疫功能的措施；若 ...

Core Viewpoint - Collagen is a crucial structural protein in the human body, essential for the function of various systems and organs. The market for collagen products, particularly in the beauty and anti-aging sectors, is expected to grow significantly over the next 30 years, highlighting the need for improved product quality in collagen biotechnology [1]. Group 1: Industry Insights - The recent controversies surrounding the efficacy claims and testing standards of topical recombinant collagen have raised concerns about the quality and safety of collagen and collagen peptide products [1]. - The beauty and anti-aging market is identified as a significant opportunity, with collagen products at the forefront of this growing biotechnology industry [1]. Group 2: Upcoming Events - A network seminar on "Collagen and Collagen Peptide Quality Testing" is scheduled for September 18, 2025, organized by Instrument Information Network and China Light Industry Press [2]. - The seminar will focus on quality control, efficacy validation, and testing technologies related to collagen and collagen peptides, providing a platform for professionals in nutrition and cosmetics industries [2]. Group 3: Seminar Agenda - The seminar will feature various sessions, including: - "Functions and Applications of Collagen and Collagen Peptides" by Hong Hui from China Agricultural University [3]. - "Quality Standards and Common Analytical Methods for Chinese Collagen Products" by Lian Chongfei from Hainan Meilun Youpeptide Biotechnology Co., Ltd. [3]. - "Purity Assessment of Collagen Based on Characteristic Amino Acid Detection" by Zheng Jiagai from Guangdong Academy of Sciences [3]. - "Emerging Trends in the Bioactive Peptide Industry" by Yi Shuangshuang from China Light Industry Press [3].

Core Viewpoint - The article discusses Sam Altman's increased investment in the biotech startup Retro Biosciences, which aims to extend human lifespan by 10 years through innovative therapies targeting aging and related diseases [3][4][33]. Investment and Company Overview - Sam Altman has invested a total of $180 million (approximately 1.3 billion RMB) in Retro Biosciences, indicating strong support for the company's mission [4]. - Retro Biosciences plans to initiate its first human clinical trial for an experimental drug, RTR242, by the end of 2025 [8][12]. - The company has previously collaborated with OpenAI to develop a model called GPT-4b-micro, designed for protein engineering [5][28]. Scientific Approach and Mechanism - RTR242 aims to enhance the cellular "garbage disposal and recycling system" to clear damaged cellular components, potentially reversing aging effects [16]. - The drug targets "cellular garbage" associated with Alzheimer's and Parkinson's diseases, aiming to restart the autophagy process in aging individuals [17]. - Retro is also developing therapies for leukemia and central nervous system diseases, indicating a broad approach to longevity [34]. Future Goals and Funding - Retro Biosciences has set an ambitious goal to increase healthy human lifespan by 10 years, focusing on maintaining health and vitality until the end of life [33]. - The company aims to raise $1 billion in its Series A funding round to support its clinical trials and research initiatives [35]. - Comparatively, other longevity companies like Altos Labs have raised over $3 billion, highlighting the competitive landscape in the longevity biotech sector [37]. Leadership and Expertise - The CEO of Retro Biosciences, Bates-Lacroix, has a strong background in protein research and has previously led successful ventures in the tech industry [44]. - The company also features a co-founder, Ding Sheng, known for his expertise in stem cell research, enhancing the company's scientific credibility [41].

Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 4.04 billion, a decrease of 12.26% year-on-year [6] - The net profit attributable to shareholders was CNY 669 million, an increase of 26.03% year-on-year [6] - The net profit excluding non-recurring items was CNY 641 million, up 27.08% year-on-year [6] - The net cash flow from operating activities was CNY 832 million, an increase of 214.97% year-on-year, indicating improved operational quality [4][6] Product Development and Research - The Baizi Bujin Capsule is an OTC Class A drug developed based on the theory of Qi and essence, aimed at anti-aging [5] - Research published in the journal Biomedicine & Pharmacotherapy (impact factor 7.42) confirmed that Baizi Bujin Capsule can improve memory and muscle endurance in aging mice, significantly reducing their DNA methylation age [3][5] - Clinical studies led by the Xiyuan Hospital of the China Academy of Chinese Medical Sciences demonstrated the capsule's effectiveness in improving symptoms of aging across various systems, including neurological and cardiovascular [3][5] Strategic Outlook - The company plans to continue its "Seventh Five-Year" strategic plan, focusing on high-quality industry development and enhancing operational management [5][7] - There is an emphasis on increasing research and development output and optimizing the marketing system to achieve steady growth [5][7] - The establishment of a subsidiary, Shanghai Yiling Pharmaceutical, aims to enhance the company's competitiveness in biopharmaceuticals [7][8] Market and Sales Strategy - The company is committed to increasing the promotion of Baizi Bujin Capsule to convert research advantages into sales advantages [8] - The company is monitoring policies related to centralized procurement and will adapt its strategies accordingly [8] - Future focus includes strengthening budget management and operational efficiency to enhance profitability [8]

Core Viewpoint - The article discusses a research paper published by a team from Rutgers University, BioViva, and Harvard University, which proposed a gene therapy using cytomegalovirus (CMV) to extend healthy lifespan in mice. The paper was later retracted due to data discrepancies identified during an internal review [5][8][12]. Research Findings - The study demonstrated that gene therapies targeting TERT and FST genes could extend the lifespan of mice by approximately 40% without increasing cancer risk [5][12]. - Mice treated with TERT gene therapy had a median lifespan of 37.5 months, while those treated with FST gene therapy had a median lifespan of 35.1 months, compared to 26.7 months for the control group [12][13]. - The therapies also improved metabolic functions, glucose tolerance, and prevented weight loss and hair loss, indicating a broader impact on health beyond lifespan extension [13]. Gene Therapy Mechanism - TERT gene therapy activates telomerase, which can extend telomeres and potentially reverse aging processes, while FST gene therapy enhances muscle mass and function [10][11]. - CMV was chosen as a delivery vector due to its ability to carry larger genetic payloads and its safety profile, as most humans are already infected with it without symptoms [11]. Retraction Reasons - The paper was retracted following the discovery of issues in the data presented in figures, including over-saturation and image duplication [15][16]. - The retraction was supported by George Church, one of the authors, who acknowledged the lack of sufficient data backup but maintained that the core findings were not fundamentally flawed [20]. Author Responses - Elizabeth Parrish expressed shock at the retraction, arguing that the image issues were non-substantial and had been previously corrected [21]. - Zhuo Hua, another co-author, indicated a lack of necessity to respond due to retirement [21]. - The first author, Dabbu Kumar Jaijyan, stated there was nothing to address regarding the retraction [22].

Core Viewpoint - The global prevalence of type 2 diabetes is rapidly increasing, with an estimated 700 million people affected by 2045, posing a significant public health threat. Aging mechanisms are closely related to the progression of diabetes, and delaying aging may be crucial for improving diabetes and other age-related diseases [3][4]. Group 1: SGLT2 Inhibitors and Aging - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are important anti-diabetic drugs that lower blood sugar by inhibiting glucose reabsorption in the kidneys. They also enhance lipid metabolism and ketone production, potentially mimicking caloric restriction (CR) and exerting anti-aging effects [3][4]. - SGLT2i can simulate the effects of caloric restriction without the need for strict dietary control, providing a more feasible alternative for anti-aging interventions in diabetic patients [4][5]. Group 2: Clinical Study Findings - A multicenter, randomized, double-blind, placebo-controlled study published in Cell Reports Medicine revealed that the SGLT2i drug Henagliflozin can extend telomere length and may exert anti-aging effects through various pathways, including the IGF-1 system, glucose metabolism, and immune function [5][6][9]. - In the clinical trial involving 150 type 2 diabetes patients, those treated with Henagliflozin showed significant increases in telomere length, insulin-like growth factor binding protein-3 (IGFBP-3) levels, and β-hydroxybutyrate levels, along with improved glucose metabolism [8][9]. - The study also indicated that Henagliflozin significantly increased granzyme B expression in cytotoxic T lymphocytes and showed trends of increased perforin expression, suggesting enhanced immune function [8][9]. Group 3: Implications and Future Research - The findings highlight the potential of SGLT2i in the anti-aging domain, with Henagliflozin receiving the highest score among nine FDA-approved drugs evaluated for anti-aging potential [6][9]. - However, there is still a lack of direct clinical data regarding the anti-aging effects of SGLT2i, indicating a need for further research in this area [6].

Core Viewpoint - A recent study identifies five unhealthy habits that significantly accelerate facial aging, making individuals appear older than their peers. These habits include smoking, lack of exercise, neglecting sun protection, unhealthy diet, and poor sleep quality [1][2]. Summary by Categories Unhealthy Habits Leading to Aging - Smoking is identified as the primary culprit of accelerated facial aging, having the most significant impact among all lifestyle habits [2]. - Lack of physical activity increases the risk of facial aging, particularly in women [2]. - Neglecting sun protection can lead to an average facial aging increase of approximately 29% compared to those who practice sun protection, with women being more affected [2][3]. - An unhealthy diet, characterized by high salt and sugar intake and low fruit and vegetable consumption, can accelerate facial aging by about 20% [3]. - Poor sleep habits, including insufficient or excessive sleep, can make the face appear nearly 20% older [4]. Recommendations to Combat Aging - Quitting smoking and avoiding secondhand smoke is crucial, as smoking damages collagen and elastin in the skin, leading to premature aging [6]. - Establishing a regular exercise routine is recommended, with a target of 150 minutes of moderate-intensity activity per week, along with strength training to combat muscle loss [7]. - Daily sun protection is emphasized as a cost-effective anti-aging measure, including wearing protective clothing and using sunscreen with SPF30 or higher [8]. - Improving diet by cooking at home and incorporating a variety of colorful fruits and vegetables can enhance skin health and reduce aging [9]. - Maintaining good sleep hygiene is essential for skin repair, including creating a dark sleeping environment and minimizing electronic device usage before bed [10].

Core Insights - The smart oxygen chamber industry, once thriving with a market size reaching approximately 770 million RMB, is now facing significant challenges, including a sharp decline in orders and business closures [1][3] - The initial boom in the industry was driven by scientific research indicating the potential of hyperbaric oxygen therapy in anti-aging, leading to a rapid market expansion [3][4] - Many new companies entered the market recently, often providing low-quality products and engaging in one-time sales, contributing to consumer dissatisfaction and business failures [3][4] Industry Overview - The global smart oxygen chamber market has reached a size of approximately 110 million USD, with China being the largest production base, accounting for 41.45% of global output [3] - The industry has seen a surge in registered companies, with many established in the last couple of years, often lacking quality assurance [3] Consumer Experiences - Numerous consumers have reported negative experiences, such as businesses disappearing after purchases and equipment malfunctioning shortly after acquisition [1][3] - Specific cases include a consumer spending 58,000 RMB on a membership that allowed only three uses before the business closed, and another spending 400,000 RMB on a malfunctioning oxygen chamber [1] Emerging Trends - Despite the downturn, companies like Rlab are expanding by leveraging advanced technology and a comprehensive business model, including the launch of a new lightweight oxygen chamber [6][9] - Rlab's innovative products have led to a significant increase in inquiries and orders, with a reported 334% growth in website consultations [6][10] Market Dynamics - The introduction of new materials, such as aerospace-grade carbon fiber, has allowed for product innovation and weight reduction, enhancing the appeal of oxygen chambers for both health management and leisure activities [6][9] - The brand has successfully penetrated both domestic and international markets, with products available in over 100 cities and exports to countries like the USA and Spain [9][10] Future Outlook - The smart oxygen chamber market is expected to evolve towards healthier practices as industry regulations are implemented, potentially making advanced anti-aging technologies accessible to a broader audience [11]